Abstracts Book - IMRC 2018

• SB6-P073
PREPARATION AND IN VITRO EVALUATION OF A
RADIOLABELLED NANOCARRIER AS AN APPROACH FOR
COMBINED THERAPY ON TRIPLE NEGATIVE BREAST CANCER
CELLS
Brenda Gibbens Bandala 1,2 , Blanca Eli Ocampo García 1 , Enrique Morales Avila 2
1 Instituto Nacional de Investigaciones Nucleares (ININ), Materiales Radiactivos, Mexico.
2 Universidad Autónoma del Estado de México, Facultad de Quimica, Mexico.
Introduction: Nanoradiopharmaceuticals have acquired more attention as
suitable approaches for theranostic applications in several cancer tumors.
Polymeric nanoparticles have generated increasing interest in this field due to
their ability to encapsulate drugs and their ability for targeted a controlled drug
delivery. Paclitaxel (PTX) has suggested remain as the standard option to treat
triple negative breast cancer (TNBC). Several side effects have been reported on
this treatment. Bombesin has demonstrated high sensitivity to detect GRPr
(Gastrin Release Peptide receptor) in all phenotypes of breast cancer. Triple
Negative Breast Cancer (TNBC) represents the worst prognosis.
Objective: The aim of this study was to obtain the 177 Lu-Bombesin-PLGA(PTX)
nanosystem as an approach potentially useful for combined therapy on triple
negative breast cancer cells through paclitaxel (PTX) targeted delivery in MDA-
MB-237 cells which overexpress GRPr and the radiotherapy produced by the β -
energy of Lutetium-177 on target site.
Methods: Nanoparticles were synthetized and characterized by SEM, FT-IR and
DLS. The Bombesin-PLGA(PTX) was radiolabelled and the cytotoxicity was
evaluated on MDA-MB-237 TNBC.
Results: The Bombesin-PLGA(PTX) obtained nanoparticles showed a spherical
structure (